Synopsys Down Over 9%, on Pace for Largest Percent Decrease Since March 2020 — Data Talk
Synopsys, Inc. (SNPS) is currently at $491.70, down $48.98 or 9.06%
--Would be lowest close since Jan. 5, 2024, when it closed at $484.81
--On pace for largest percent decrease since March 16, 2020, when it fell 13.19%
--Currently down three of the past four days
--Currently down two consecutive days; down 11.93% over this period
--Worst two day stretch since the two days ending Aug. 20, 2004, when it fell 30.45%
--Down 4.51% year-to-date
--Down 20.86% from its all-time closing high of $621.30 on July 5, 2024
--Up 11.39% from 52 weeks ago (Aug. 4, 2023), when it closed at $441.42
--Down 20.86% from its 52-week closing high of $621.30 on July 5, 2024
--Up 15.94% from its 52-week closing low of $424.10 on Aug. 17, 2023
--Traded as low as $487.40; lowest intraday level since Jan. 5, 2024, when it hit $477.65
--Down 9.85% at today's intraday low; largest intraday percent decrease since March 16, 2020, when it fell as much as 15.98%
--Eighth worst performer in the S&P 500 today
--Seventh worst performer in the Nasdaq 100 today
All data as of 11:00:19 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 02, 2024 11:18 ET (15:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks